trueffelpix-shutterstock-com
Trueffelpix / Shutterstock.com
21 January 2016AmericasKevin O’Connor

Patentability of diagnostics: reasons for optimism

Over the last five years, US courts have consistently declared patent claims covering diagnostics ineligible for protection. As in other fields, the vulnerability of such claims to eligibility challenges undermines confidence in the ability to protect intellectual property assets using the patent system. However, other avenues of protection (eg, trade secrets) for diagnostic tests may be limited in view of commercialisation and/or regulatory requirements. Innovative companies should glean guidance from these cases and continue to pursue patent protection for their diagnostic tests.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
8 May 2026   LSIPR's senior reporter Marisa Woutersen speaks with Mythili Markowski of Regeneron on why new USPTO guidance is putting post-grant proceedings under the spotlight and how in-house teams are responding.
Americas
7 May 2026   A California judge has denied Corcept’s bid to dismiss the lawsuit over its drug for a rare hormonal disorder, allowing the litigation to proceed on all core counts.
Americas
5 May 2026   J&J’s Abiomed can proceed with its non-infringement defence despite potential future appellate reversal, in a week when both parties in the case were dealt wins and losses in their clash over Impella devices.